Roivant & Pfizer Form New Vant Company to Develop TL1A Drug Candidate

Roivant & Pfizer Form New Vant Company

Roivant & Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases  Roivant Sciences and Pfizer Inc.has announced formation of a new Vant to develop and commercialize PF-06480605 (now RVT-3101). RVT-3101 is a fully human monoclonal antibody targeting TL1A, which is currently in Phase 2b development in ulcerative colitis (UC). […]

Roivant & Pfizer Form New Vant Company Read More »